Static Image
Synvisc-One Injections Recalled

Synvisc-One Injections Recalled

Biotech giant Sanofi Genzyme has initiated a voluntary product recall for one lot of Synvisc-One, a brand of hyaluronic acid. The lot, which was found to contain contamination, has been linked to an unexpected increase in side effects. In an urgent “product hold” letter, doctors, clinics and pharmacies who received syringes from that lot were instructed to immediately stop using the injections on patients until the company can investigate. “The voluntary product recall of one (1) lot of Synvisc One, lot 7RSL021, is due to an ongoing investigation which revealed the presence of microbial contamination,” said Sanofi spokesperson Heather Guzzi in ...more
An Early Look at the New Psoriatic Arthritis Treatment Guideline

An Early Look at the New Psoriatic Arthritis Treatment Guideline

Physicians will soon have a new guideline for the management of psoriatic arthritis (PsA). This ambitious undertaking, the details of which were presented recently at the American College of Rheumatology (ACR) Annual Meeting, involved a large panel of experts who analyzed and synthesized the best available evidence to create and support the recommendations. The proposed guideline – which contains approximately 80 recommendations – will undergo final review prior to consideration for publication in 2018 in the journals Arthritis Care & Research and Arthritis & Rheumatism. It will help rheumatologists select treatments for their psoriatic arthritis patients based on the best available evidence, especially in light of all the new treatments recently approved for PsA by the Food and Drug Administration (FDA). A Need for a PsA Guideline?  “ had formal guidelines for PsA before, but now we have a lot of new treatment options for the management of this disease,” says Jasvinder Singh, MD, head of the panel ...more
Become a PARTNER to Help Find a Cure

Become a PARTNER to Help Find a Cure

Juvenile arthritis (JA) affects nearly 300,000 kids and families in the United States. Of all the forms of arthritis, juvenile idiopathic arthritis (JIA) is the most common type of arthritis in children. For almost seven decades, the Arthritis Foundation has upheld our unwavering promise to assist them and their caregivers. In an ongoing effort to include the patient voice in everything we do, we’re asking you – patients, parents, loved ones and others with a connection to JIA – to tell us what JIA research matters to you. The Arthritis Foundation is a member of PARTNERS, a network of patients, parents, ...more
Platinum Ambassador Spotlight—Rebecca Gillett, Colorado

Platinum Ambassador Spotlight—Rebecca Gillett, Colorado

In 2016, I was fortunate to attend the Arthritis Foundation Advocacy Summit in Washington D.C. alongside some seasoned advocacy veterans from Denver. I had never met with my legislators or shared my story before, so it was a new experience. It was easy to “catch the bug” for advocacy being surrounded by so many other fellow arthritis patient advocates who want to make a difference for all of us. Raising awareness and fundraising for arthritis has been an integral part of my life for the past several years, but advocacy has become an even greater passion. This year, I achieved ...more
#AsktheAF: Open Enrollment Edition!

#AsktheAF: Open Enrollment Edition!

During this season of open enrollment, the Arthritis Foundation is here to help you make an informed decision in selecting the best health coverage for your unique needs. Open enrollment is the time of year when individuals elect health care benefits through their employer, Medicare, Medicaid, or the federal and state health exchanges created through the Affordable Care Act. Open enrollment periods vary based on the type of insurance you have, but generally occur in the late fall. As part of our commitment, the Arthritis Foundation hosted a webinar last month to provide a general overview of open enrollment and the ...more
Research Identifies Which RA Patients May Successfully Reduce Their Biologics

Research Identifies Which RA Patients May Successfully Reduce Their Biologics

A new study presented recently at the 2017 Annual Meeting of the American College of Rheumatology identifies four factors that may predict which rheumatoid arthritis (RA) patients might successfully taper the dose of their biologic medication. Although biologics are highly effective in controlling RA and its symptoms, patients in some cases prefer not to use them. Past studies have shown that it is possible to taper and even stop the medication in certain patients who are in remission once they have been successfully treated with one of these drugs. Reducing the dose of biologics is attractive for several reasons. These drugs are ...more
Ambassador Spotlight – Lori Fagan, Virginia

Ambassador Spotlight – Lori Fagan, Virginia

From Lori Fagan I have been living with rheumatoid arthritis (RA) for over a decade. As a full-time working mom and wife living with a chronic condition, the last thing I need is the added strain of fighting with my health insurer. Unfortunately, because of a common health insurance practice known as “step therapy,” the last 10 years have been a constant and stressful battle. Step therapy, sometimes known as “fail first,” is when an insurer requires you to try and fail on one or more therapies preferred by the insurer before the patient is allowed to have the medication the physician deems ...more
Type 2 Diabetes Risk May Be Higher With RA

Type 2 Diabetes Risk May Be Higher With RA

People who have rheumatoid arthritis (RA) are known to be more likely to develop other serious health problems, including heart disease, lung disease and some types of cancer. Now a recent study in the online journal PLOS One appears to indicate they also have a higher risk of developing type 2 diabetes. Lead study author Piero Ruscitti, MD, of the University of L’Aquila in Italy, writes that he and his colleagues undertook the study to show that type 2 diabetes is common but often overlooked in RA patients. For the study, the researchers followed 439 people with newly-diagnosed RA for one year, evaluating ...more
Arthritis Foundation Plays a Role in CMS Biosimilars Policy Reversal  

Arthritis Foundation Plays a Role in CMS Biosimilars Policy Reversal  

On Thursday, November 2, the Centers for Medicare and Medicaid Services (CMS) announced they would reverse a policy determining how providers are paid for administering biosimilar drugs under Medicare Part B. A biosimilar is a type of medication that is “similar” to a biologic reference product, approved by the Food and Drug Administration (FDA); biosimilars offer patients the promise of more affordable treatment options available on the market to address their disease. Over the past twenty-four months, the Arthritis Foundation and other patient organizations have expressed our collective concerns with CMS’s biosimilars reimbursement policy and encouraged them to reverse it. This ...more
When A Back or Neck Ache Means You Have OA

When A Back or Neck Ache Means You Have OA

Maybe you overdid it cleaning the house or sprucing up your garden this weekend. Or you’re using a hot or cold pack on your lower back more often over the past few months. Does the pain come and go or seem to be getting worse? Then, it might be time ask your doctor if you have osteoarthritis (OA) in your spine (that runs from the neck to the lower back). As you age, the cartilage lining the joints of your spine wears down, allowing the bones to rub together, causing back pain and stiffness. Other causes of spinal OA include injury, ...more